Trial · NCT05328154
MAGnesium Effect With ANtiosteoporotic Drugs
NCT05328154, Phase 2, Completed, University Hospital, Clermont-Ferrand
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MAGnesium Effect With ANtiosteoporotic Drugs. Trials, record NCT05328154. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05328154
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MAGnesium Effect With ANtiosteoporotic Drugs
- NCT number
- NCT05328154
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 45 participants, actual
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation
- First posted
- 2022-04-14
- Last updated
- 2024-12-27
- Other registries' IDs
- eudract:2021-005401-28
Source ClinicalTrials.gov
Registered outcomes60
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | C-terminal telopeptides of collagen type 1 (CTX) dosage | Visit 0: Day 0-1 month | Evaluation of the CTX evolution after one year, defined as the difference \[after - before\], relative to the basal value (ng/ml). For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Primary | C-terminal telopeptides of collagen type 1 (CTX) dosage | Visit 3: Day 0+1 year | Evaluation of the CTX evolution after one year, defined as the difference \[after - before\], relative to the basal value (ng/ml). For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | N-terminal propeptide of procollagen type 1 (P1NP) dosage | Visit 1: Day 0 | The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | N-terminal propeptide of procollagen type 1 (P1NP) dosage | Visit 3: Day 0+1 year | The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Osteocalcin dosage | Visit 1: Day 0 | The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes |
| Secondary | Osteocalcin dosage | Visit 3: Day 0+1 year | The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes |
| Secondary | Sclerostin dosage | Visit 1: Day 0 | The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Sclerostin dosage | Visit 3: Day 0+1 year | The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Periostin dosage | Visit 1: Day 0 | The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Periostin dosage | Visit 3: Day 0+1 year | The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41566091 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05328154
GET https://conductscience.org/api/trials/v1/NCT05328154/registered?page=2